Projects
Novel therapeutic targets in inflammatory bowel disease - Translational research in IBD Ghent University
This workpackage regroups multiple activities overall aiming at the determination of the expression level of GLPG targets, factors on or downstream of the target pathway and the activation level of target pathways in blood and in colon samples from IBD patients. Different conditions will be compared
Multiple techniques will be applied ranging from micro-array analysis and QPCR validation to immunehistochemistry and in situ ...
A family history of inflammatory bowel disease (IBD). KU Leuven
We aim to identify the genetic variant(s) that can explain familial aggregation in selected multiple-affected IBD families most likely driven by one or a few genetic factors with intermediate-to-strong effect. Second to identify the shared genetic susceptibility variants between IBD and other diseases using families with members suffering from IBD and concomitant diseases.
Influence of microbiota on intestinal stem cell behaviour and differentiation in inflammatory bowel diseases. KU Leuven
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two major forms of inflammatory bowel diseases (IBD), which are chronic and progressive diseases of the gastrointestinal tract. The exact cause is unknown, but it has been suggested that the diseases result from an abnormal immune response towards environmental factors, such as the microbiota, in a genetically predisposed person. Current therapies aim to stop this inflammatory cascade. ...
LONG-TERM SEQUENTIAL USE OF BIOLOGIC THERAPIES IN INFLAMMATORY BOWEL DISEASE: HARMLESS OR HAZARDOUS? KU Leuven
Inflammatory bowel diseases (IBD) are illnesses that are characterized by chronic inflammation of the gut. To prevent the development of complications and to improve quality of life it is necessary to start treatment, which often includes biologic therapies or biologicals. The latter are designed to block specific pathways in our immune system to restore the dysbalance seen in disease state and due to the chronicity of IBD they need to be ...
Trp-IBD: Tryptophan for persistent fatigue in quiescent Inflammatory Bowel Disease: a double-blind placebo-controlled clinical trial Ghent University
The end use of this project proposal is to provide evidence for the attribution of a therapeutic property to the dietary supplement tryptophan (Trp) for pathological fatigue in patients with inflammatory bowel disease (IBD) in remission. It offers gastroenterologists and general practitioners the opportunity to treat this persistent complaint in their patient population, through a means that is widely available and safe.
Mucosal proteases and their inhibitors in inflammatory bowel disease: from etiopathogenetic insight to innovative therapy. KU Leuven
Endothelial dysfunction in inflammatory bowel disease: a target for therapeutic intervention? Ghent University
The contribution of blood vessel dysfunction in inflammatory bowel disease (IBD) has not been investigated thus far. We want to validate the presence of blood vessel dysfunction in IBD and test the therapeutic effect of two established blood vessel-normalizing strategies in mouse models of intestinal inflammation (selective knock-out of endothelial PHD2 and neutralizing antibodies directed against placental growth factor).
Pharmacometric models to improve therapeutic drug monitoring of monoclonal antibodies in the treatment of inflammatory bowel diseases KU Leuven
Inflammatory bowel diseases (IBD) are chronic, relapsing, inflammatory conditions of the gastrointestinal (GI) tract. Ulcerative colitis (UC) and Crohn’s disease (CD) are the primary subtypes of IBD. Although the etiology remains incompletely understood, it is generally accepted that IBD is the result of an inappropriate host response to environmental factors in genetically susceptible individuals. In Western Europe, prevalence of UC is ...